文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

索格列净在糖尿病合并慢性肾脏病患者中的应用

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
PubMed 文献 · N Engl J Med · 2020-11-16
一句话结论糖尿病合并CKD患者使用索格列净可降低心血管死亡、心衰住院和心衰紧急就诊的复合终点风险(HR 0.74),但腹泻、生殖器真菌感染、容量不足和糖尿病酮症酸中毒更常见。

SCORED试验为多中心双盲RCT,纳入10584例2型糖尿病(HbA1c≥7%)、CKD(eGFR 25-60 ml/min/1.73m2)且有心血管风险的患者,随机接受索格列净或安慰剂,中位随访16个月。主要终点(心血管死亡、心衰住院和心衰紧急就诊的复合终点)事件率索格列净组5.6/100患者年 vs 安慰剂组7.5/100患者年(HR 0.74;95%CI 0.63-0.88;P<0.001)。心血管死亡无显著差异(HR 0.90;95%CI 0.73-1.12;P=0.35)。腹泻、生殖器真菌感染、容量不足和糖尿病酮症酸中毒在索格列净组更常见。

要点

  • 糖尿病合并CKD(eGFR 25-60 ml/min/1.73m2)且HbA1c≥7%的患者,索格列净降低心血管死亡、心衰住院和心衰紧急就诊复合终点(HR 0.74;95%CI 0.63-0.88;P<0.001)。
  • 心血管死亡单独终点无显著获益(HR 0.90;95%CI 0.73-1.12;P=0.35)。
  • 索格列净组腹泻、生殖器真菌感染、容量不足和糖尿病酮症酸中毒发生率高于安慰剂组。
  • 试验因资金丢失提前终止,中位随访仅16个月。
  • 主要终点在试验期间被更改。

适用人群与场景

  • 2型糖尿病(糖化血红蛋白≥7%)、慢性肾脏病(eGFR 25-60 ml/min/1.73m2)且有心血管风险的患者。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及索格列净的具体剂量、给药途径、频次或疗程。

红旗征与不能漏的情况

  • 腹泻、生殖器真菌感染、容量不足和糖尿病酮症酸中毒在索格列净组更常见。

研究设计与关键结果

  • 多中心双盲RCT,筛查19188例,纳入10584例,索格列净组5292例,安慰剂组5292例,中位随访16个月。
  • 主要终点(心血管死亡、心衰住院和心衰紧急就诊的复合终点)事件率:索格列净组5.6/100患者年 vs 安慰剂组7.5/100患者年(HR 0.74;95%CI 0.63-0.88;P<0.001)。
  • 心血管死亡事件率:索格列净组2.2/100患者年 vs 安慰剂组2.4/100患者年(HR 0.90;95%CI 0.73-1.12;P=0.35)。
  • 原复合终点(心血管死亡、非致死性心肌梗死或非致死性卒中的首次发生):HR 0.84(95%CI 0.72-0.99)。
  • 原复合终点(心血管死亡或心衰住院的首次发生):HR 0.77(95%CI 0.66-0.91)。
  • 不良事件:腹泻、生殖器真菌感染、容量不足和糖尿病酮症酸中毒在索格列净组更常见。
  • 试验因资金丢失提前终止;主要终点在试验期间被更改。

证据类型、等级与局限

  • 研究类型:多中心、双盲、随机对照试验(RCT)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:试验因资金丢失提前终止;主要终点在试验期间被更改;中位随访仅16个月。

对床旁实践的改变

  • 对于2型糖尿病合并CKD(eGFR 25-60 ml/min/1.73m2)且有心血管风险的患者,索格列净可降低心血管死亡、心衰住院和心衰紧急就诊的复合终点风险。
  • 使用索格列净时需警惕腹泻、生殖器真菌感染、容量不足和糖尿病酮症酸中毒。

指南或共识出处

  • 原文未提及指南或共识名称;试验名称:SCORED;ClinicalTrials.gov编号:NCT03315143;资助方:Sanofi和Lexicon Pharmaceuticals。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.

METHODS: We conducted a multicenter, double-blind trial in which patients with type 2 diabetes mellitus (glycated hemoglobin level, ≥7%), chronic kidney disease (estimated glomerular filtration rate, 25 to 60 ml per minute per 1.73 m2 of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding.

RESULTS: Of 19,188 patients screened, 10,584 were enrolled, with 5292 assigned to the sotagliflozin group and 5292 assigned to the placebo group, and followed for a median of 16 months. The rate of primary end-point events was 5.6 events per 100 patient-years in the sotagliflozin group and 7.5 events per 100 patient-years in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.63 to 0.88; P<0.001). The rate of deaths from cardiovascular causes per 100 patient-years was 2.2 with sotagliflozin and 2.4 with placebo (hazard ratio, 0.90; 95% CI, 0.73 to 1.12; P = 0.35). For the original coprimary end point of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, the hazard ratio was 0.84 (95% CI, 0.72 to 0.99); for the original coprimary end point of the first occurrence of death from cardiovascular causes or hospitalization for heart failure, the hazard ratio was 0.77 (95% CI, 0.66 to 0.91). Diarrhea, genital mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozin than with placebo.

CONCLUSIONS: In patients with diabetes and chronic kidney disease, with or without albuminuria, sotagliflozin resulted in a lower risk of the composite of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure than placebo but was associated with adverse events. (Funded by Sanofi and Lexicon Pharmaceuticals; SCORED ClinicalTrials.gov number, NCT03315143.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2020. PMID: 33200891. doi:10.1056/NEJMoa2030186

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。